Lupin has received final approval for its Fluocinonide Topical Solution USP, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. Fluocinonide Topical Solution USP, 0.05% had US sales of $32.4 million, as per IMS MAT March 2017.
Lupin’s Fluocinonide Topical Solution USP, 0.05% is AT rated generic equivalent of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
